{"url_path":"/sec/otlk/8-k/2026-05-13/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","accession_number":"0001104659-26-060305","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":112,"has_tables":true,"body_markdown":"**Item 1.02 Termination of a Material Definitive Agreement.**\n\n \n\nIn connection with entering into the Sales Agreement, the Company terminated,\neffective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”)\nwith BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its\nsole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Prior ATM Program”).\nAs a result of the termination of the Prior Sales Agreement, the Company will not offer or sell any additional shares of Common Stock\nunder the Prior ATM Program."}